Produces the Impella product line, the world's smallest, minimally invasive, high performance micro blood pump

Leading provider of mechanical circulatory support devices, offering a continuum of care to heart failure patients

Abiomed (Nasdaq: ABMD) develops products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its main family of products, Impella, is used in the cardiac catheterization lab by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Company’s main products include Impella 2.5, Impella 5.0, Impella CP, Impella RP, and Symphony. Abiomed generated FY 2013 Sales of ~$160M. The Company was founded in 1981, sells its products around the globe, and has over 500 employees.

Transaction Summary

  • In 2007, Essex Woodlands acquired a stake in the publicly traded shares of Abiomed, and subsequently made an additional investment in 2008

Related News

“EW has become a partner and advisor to Abiomed. We value the strategic guidance we receive from their team on investment and business decisions.”

Michael R. Minogue

Chairman, President and CEO, Abiomed